Supplementary Table 1 from GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <i>In Vitro</i> and <i>In Vivo</i>
收藏NIAID Data Ecosystem2026-05-16 收录
数据链接：
官方服务：
资源简介：
XLS file, 36KB, Summary of Breast Cancer Cell Growth Inhibition and Bliss Sums After Treatment with GDC-0941, Docetaxel (DTX) or the Combination of Both Drugs.
创建时间：
2012-07-15
